CAJ | 학술논문

三阴乳腺癌(TNBC)因浸润性较强是乳腺癌中预后不佳的一种亚型,其治疗已受到广泛关注,但尚无明确的标准.TNBC在新辅助化疗中可获得12％～48％的病理完全反应率(pCR),高于其他类型乳腺癌,但其pCR在文献报道中波动幅度较大.辅助化疗在早期TNBC中的应用仍存在争议,有学者主张使用不含蒽环类药物的化疗方案.紫杉类、蒽环类等细胞毒性药物仍是目前TNBC解救化疗的主力药物,临床试验显示,联合应用吉西他滨或卡培他滨可延长患者生存期.ADP-核糖聚合酶(PARP)成为TNBC靶向治疗新的研究靶点,对其抑制剂如BSI-201和Olaparib的深入研究有望为临床治疗提供更多有效的选择.
삼음유선암(TNBC)인침윤성교강시유선암중예후불가적일충아형,기치료이수도엄범관주,단상무명학적표준.TNBC재신보조화료중가획득12％～48％적병리완전반응솔(pCR),고우기타류형유선암,단기pCR재문헌보도중파동폭도교대.보조화료재조기TNBC중적응용잉존재쟁의,유학자주장사용불함은배류약물적화료방안.자삼류、은배류등세포독성약물잉시목전TNBC해구화료적주력약물,림상시험현시,연합응용길서타빈혹잡배타빈가연장환자생존기.ADP-핵당취합매(PARP)성위TNBC파향치료신적연구파점,대기억제제여BSI-201화Olaparib적심입연구유망위림상치료제공경다유효적선택.
Triple-negative breast cancer ( TNBC ) is a subtype of breast cancer,and it is characterized by an aggressive clinical course with a poor prognosis.Treatment for TNBC has attracted much attention in recent years,however,there is no standard treatment for TNBC in clinical setting.The pCR rates of neoadjuvant chemotherapy in TNBC ranges from 12％ to 48％ in the current published data,and it is higher than that in other types of breast cancer,however,the fluctuating range of the TNBC ’s pCR is large in literature.Although the administration of adjuvant chemotherapy for early TNBC is controversial,the regimen without anthracyclines is reported to be suitable for early TNBC patients.Standard cytotoxic agents including taxanes and anthracyclines are still the main choices for TNBC salvage treatment,and the combination with gemcitabine or capecitabine may improve the overall survival.Poly (ADP-ribose) polymerase (PARP) is a new molecular target for TNBC in ongoing studies.Further research on the target-inhibitors such as BSI-201and Olaparib will provide more effective choices to clinical treatment.